Thrilled to host Matt Cooper of MCW Surgery on this timely episode on Delayed Graft Function. podcasts.apple.com/us/podcast/lif… We talk about organ waste and making the most of lifesaving gifts. Check out the AJKD article here free for #DonateLifeMonth ajkd.org/article/S0272-…

Surprised to see losartan topping this list.

When starting an ARB, losartan is the last option I'd go with, for one simple reason.

🧵 /1

13/n
Waiting for the #FLOW trial results, #Semaglutide shows a 24% reduction in CKD progression in T2D patients
The trial has been stopped for ethical reasons because the Semaglutide group had much better results.
novonordisk.com/news-and-media…

12/n
Trials showed improved composite kidney outcomes in T2D treated with GLP-1R agonist
However no trials yet in non diabetic patients

8/n
GLP-1 R agonists are the GAME CHANGERS now in many metabolic diseases 🤾
Is it a metabolic magic pill?
Find more at 👉
ncbi.nlm.nih.gov/pmc/articles/P…

1/n
🚨Welcome to #NephMadness tweetorial on Gila Monster 🦎
How can Gila The NephMadness Monster, who lives in the deserts help with the obesity epidemic?
According to World Health Organization (WHO), globally 1/8 persons is obese 👇
who.int/news-room/fact…

Wondering what to do on a snowy Sunday afternoon ? Listen to the Freely Filtered: A NephJC Podcast podcast on #AnimalHouse NephMadness So informative and funny ! Joel M. Topf, MD FACP Swapnil Hiremath @[email protected] Joshua Waitzman, MD PhD Sophia Ambruso Dr. Kelly Hyndman #NephPodCrawl

17) Learning points:
♀️ who remained in the screening “up-to-date” states may be:
📌 Healthier
📌More likely to be listed on the transplant waiting list
📌Policymakers to consider a personalized & risk-based approach to breast🦀 screening in ♀️ on maintenance dialysis

15)
🌟Current study suggests a “one-size-fits all” approach to cancer screening may be inappropriate for ♀️ on dialysis
🌟Requires careful evaluation of accuracy of screening tools, frequency, pts’ choices, cost-benefit & benefits-to-harm ratio & consequences of diagnosis & Rx

14a) Hence, current guidelines recommend a #shared -decision approach to cancer screening, considering individuals’ risk, life expectancy, potential harms, values, & preferences.

12)
📌Numerically, in “up-to-date” screening states, incidence of:
📈Breast cancer may be ⬆️
📉Breast cancer deaths may be ⬇️

📌On the contrary, in “not- up-to-date” screening states, incidence of:
📈Non Breast cancer-related death: ⬆️

7b) Here is the link to the #researchletter KIReports
From Amit Garg Eric Au Jonathan Craig Stephanie Dixon ArmandoTeixeiraPinto Germaine Wong

kireports.org/article/S2468-…

2) Our returning faculty is Subashri Subashri ( #nephrologist from Chennai 🇮🇳)
Our topic: Breast Cancer Screening, Incidence, and Mortality in Women Treated with Maintenance Dialysis: A Population-Based Cohort Study in Ontario 🇨🇦
#MedTwitter #nephtwitter Int Society of Nephrology

Great Chefs of the West with our wonderful University of Colorado Nephrology #NKF #DenverRestaurantWeek

Just for you Sophia Ambruso
#NephMadness
pbslearningmedia.org/resource/c8f2b…

'But if you stop a weight loss drug like Ozempic

All the weight just comes back.

It's just like holding a beach ball underwater'

Yes.

And No.

📕Make Sure To Bookmark✅

/1

😊Fantastic talk by Javier Neyra at University of Colorado Nephrology on ‘Novel concepts on #AKI risk-classification and management’

Fun times exploring the #Denver food scene!!

highly recommend the food and cocktails El Five Denver, great view also 🏙️

John Montford

The 24% reduced primary outcome is a composite of

-kidney failure
- 50% reduction in GFR
- renal or CV death

More here pubmed.ncbi.nlm.nih.gov/36651820/ of baseline/protocol paper in NDT

#NephMadness #AnimalHouseRegion

Some more data (ahem, one datapoint) from the FLOW RCT released from Novo Nordisk

novonordisk.com/news-and-media…

The effect size of 1 mg semaglutide was 24% in the FLOW trial

The Gila The NephMadness Monster would be glad
#NephMadness

Kicking off PodCast/Tweetorial rotation with Pod 2, #TheCastAways ! Nephrology Education Collective Internship Montxu Larrazabal, M.D. Anjana Gopal Sejal Lakhani Corina Teodosiu 🕊️ 🇺🇦 Anju Yadav MD FASN FNKF Sophia Ambruso Brian Rifkin, MD Milagros Flores